Brentuximab vedotin is a CD30 directed antibody drug conjugate used for the treatment of patients with: Hodgkin lymphoma after unsuccessful autologous stem cell transplant (ASCT) or after at least two prior unsuccessful multi-agent chemotherapy regimens in those who are not ASCT candidates. Systemic anaplastic large cell lymphoma after at least one prior unsuccessful multi-agent chemo regimen.
Dosage: The recommended dose of brentuximab vedotin is 1.8 mg/kg, which must be administered as an intravenous infusion over 30 minutes every 3 weeks. Reduce dose in patients with mild hepatic impairment. The treatment should be continued until disease is progressive or unacceptable toxicity occurs.
Side Effects: The most commonly reported brentuximab vedotin side effects include:
- Peripheral sensory neuropathy
- Upper respiratory tract infection
Warnings and Precautions:
- Monitor patients with brentuximab dosage for symptoms of neuropathy, such as hyperesthesia, hypoesthesia, paresthesia, a burning sensation, discomfort, neuropathic pain, or weakness.
- Cases of infusion-related reactions, including anaphylaxis, have occurred with brentuximab therapy. Patients should be monitored during infusion.
- Avoid conceiving pregnancy during brentuximab 50 mg treatment. Appropriate contraceptive precautions should be considered.
- Do not breastfeed while taking this medication.
- Do not take any vaccination or immunization, aspirin or any other product containing Aspirin without a healthcare professional’s approval.